结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5% [1] ，但与其预后密切相关，并已成为 ...

both receptors negative or unknown); preoperative HER2-directed therapy (trastuzumab alone vs. trastuzumab plus an additional HER2-directed agent); and pathological nodal status after neoadjuvant ...

In the article that accompanies this editorial, 16 the authors report clinical outcomes from the Japanese phase III JBCRG-M06/EMERALD trial, which compared first-line eribulin plus dual human ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Patients with residual invasive HER2-positive early breast cancer after neoadjuvant systemic therapy have a poor prognosis. Adjuvant therapy with trastuzumab emtansine has shown improved outcomes.

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...

Mridula George, MD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, and associate program director for breast medical oncology program in the division of medical ...